Commercial Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 4, 2026 BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Post navigation Previous: Celcuity strengthens case for ASCO-spotlighted breast cancer drugNext: Part D Retail Prescription Drugs Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026